SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2021 / Cilt: 69 - Sayı: 1

The effect of tocilizumab on severe COVID-19 infection: Review of current evidence

Ağır COVID-19 enfeksiyonunda tosilizumab'ın etkinliği: Güncel çalışmaların derlemesi

Asiye KANBAY
Ahmet Cemal PAZARLI
Handan İNÖNÜ KÖSEOĞLU
Halil İbrahim YAKAR
Pages
74–83
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The COVID-19 outbreak that spread in December 2019 has caused the death of millions of people in a short time.
📊
Key Findings & Data:Many studies published recently have shown that many cytokines (interleukin (IL) IL-1, IL-2, IL-6, TNF and IFN-) are significantly increased in COVID-19 patients with pneumonia, and especially IL-6 in combination with other cytokines has shown to be the main cause of the cytokine storm.
💡
Conclusion & Impact:Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

The COVID-19 outbreak that spread in December 2019 has caused the death of millions of people in a short time. Many studies published recently have shown that many cytokines (interleukin (IL) IL-1, IL-2, IL-6, TNF and IFN-) are significantly increased in COVID-19 patients with pneumonia, and especially IL-6 in combination with other cytokines has shown to be the main cause of the cytokine storm. Since IL-6 level is associated with clinical worsening in COVID-19 patients, anti-IL-6 therapy is seen as a promising treatment. Tocilizumab, a widely used IL-6 antagonist, was approved by the FDA in 2017 for Cytokine Storm Syndrome (CSS). Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation

Özet

Aralık 2019’da başlayan COVID-19 salgını, kısa sürede milyonlarca insanın ölümüne yol açmıştır. Yakın zamanda yayınlanan çalışmalar, pnömoni ile seyreden COVID-19 hastalarında birçok sitokinin (IL-1, IL-2, IL-6, TNF ve IFN-γ) önemli ölçüde arttığını ve özellikle Interlökin 6 (IL-6)’nın diğer sitokinlerle birlikte sitokin fırtınasının ana nedeni olduğunu göstermiştir. IL-6 düzeyi, COVID-19 hastalarında klinik kötüleşme ile ilişki bulunduğundan dolayı, anti-IL 6 tedavisi umut vaad eden tedavi olarak görülmektedir. Yaygın kullanılan IL-6 antagonisti olan Tosilizumab’ın 2017 yılında FDA tarafından Sitokin Fırtınası Sendromu için kullanımı onaylanmıştır. Kanda IL-6 düzeyi yükselmiş, akciğerde bilateral yaygın infiltrasyonu nedeniyle oksijen satürasyonu

🔖

Cite This Article

KANBAY, A., PAZARLI, A. C., KÖSEOĞLU, H. İ., YAKAR, H. İ. (2022). The effect of tocilizumab on severe COVID-19 infection: Review of current evidence. Tüberküloz ve Toraks, Cilt: 69 - Sayı: 1, 74–83. https://ajindex.com/articles/618295

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. World Health Organization (WHO). Coronavirus Disease (COVID-19) Dashboard. Accessed date: 15 Nov 2020. Available from:
  2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62
  3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846-8
  4. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol 2020; 30(6): 1-9
  5. Cortegiani A, Ippolito M, Ingoglia G, Einav S. Chloroquine for COVID-19: rationale, facts, hopes. Crit Care 2020; 8; 24(1): 210
  6. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020; 21; 50(SI-1): 620-32
  7. The U.S. Food and Drug Administration. Information for ACTEMRA. Accessed date: 15 Nov 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/125276s114lbl.pdf
  8. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76(1): 16-32
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506
  10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMed 2020; 55: 102763
  11. Zhai H, Liu Y, Wang Y, Li X, Li T. The pathogen distribution and its influence on inflammatory factors in old patients with heart failure complicated with pulmonary infection. Tianjin Med J 2018; 46(9): 952-5
  12. Yonggang Z, Binqing F, Xiaohu Z, Dongsheng W, Changcheng Z, Yingjie Q, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Nat Sci Rev 2020; 7(6): 998- 1002
  13. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graftversus-host disease: a critical efector role for interleukin-1. Transplant Proc 1993; 25(1 Pt 2): 1216-17
  14. De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human infuenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 20